Supriya Lifescience Limited — Updates, 25-01-2025: Press Release

Supriya Lifescience delivered strong performance in Q3 FY25, with revenue rising 33% year-over-year to Rs 185.65 crore, up from Rs 140.07 crore in Q3 FY24. Gross profit surged 45% to Rs 123.87 crore, while EBITDA increased to Rs 68.05 crore, representing an impressive EBITDA margin of 36.66%, an improvement of 485 basis points YoY. The standout figure was a 125% jump in Profit After Tax (PAT) to Rs 46.78 crore, translating to a PAT margin of 25.2%, compared to 14.84% in the same quarter last year. Chairman Dr. Satish Wagh emphasized the company's operational excellence and strategic growth, highlighting both robust market presence and efficient execution across diverse therapeutic segments. This performance bodes well for the company's prospects, underscoring a positive outlook as it continues to capitalize on growth opportunities in the global API market.